Today: 18 January 2026
Subscribe
Browse Category

Biotech News 21 December 2025 - 30 December 2025

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

NEW YORK, December 30, 2025, 2:30 PM ET — Regular session Shares of Catalyst Pharmaceuticals, Inc. fell 3.0% to $23.33 in afternoon trading on Tuesday. The stock has traded between $23.30 and $24.10 so far in the session. The drop matters because trading can get choppy in the final days of the year, when fewer investors are active and price…
30 December 2025
····
Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

NEW YORK, December 30, 2025, 2:56 PM ET — Regular session Amgen Inc. shares were down 0.4% at $328.32 at 2:56 p.m. ET on Tuesday, after trading between $325.90 and $330.18. The modest move matters because investors are grading Amgen’s pipeline for new growth while several mature products face price pressure and biosimilar competition. Oncology and obesity remain two key…
30 December 2025
····
Soleno Therapeutics stock slides today: SLNO drops on investor-alert headline as biotech sector slips

Soleno Therapeutics stock slides today: SLNO drops on investor-alert headline as biotech sector slips

NEW YORK, December 30, 2025, 2:16 PM ET — Regular session Shares of Soleno Therapeutics, Inc. fell 3.1% to $46.09 in afternoon trading on Tuesday, after a law firm said it was investigating potential claims on behalf of investors. The drop outpaced declines in biotech benchmarks, with the SPDR S&P Biotech ETF down about 1.4% and the iShares Nasdaq Biotechnology…
30 December 2025
··
Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus

Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus

NEW YORK, December 30, 2025, 02:05 PM ET — Regular session Zenas BioPharma Inc shares fell $2.02, or 5.2%, to $37.03 in afternoon trading on Tuesday, after ending the prior session at $39.05. The stock ranged from $36.94 to $40.50, with about 123,000 shares traded. The drop came as biotech stocks eased in thin year-end trading, with the Nasdaq Biotechnology…
30 December 2025
····
Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

NEW YORK, December 30, 2025, 13:47 ET — Regular session Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares were down 3.6% at $67.09 at 1:47 p.m. ET on Tuesday, after trading between $65.94 and $69.95. The stock’s drop came as biotech weakened but the wider market held steady, a setup that can amplify moves in higher-volatility drug developers. The SPDR S&P Biotech ETF…
30 December 2025
···
Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

NEW YORK, December 30, 2025, 13:33 ET — Regular session Rhythm Pharmaceuticals shares were down 4.2% at $107.85 at 1:33 p.m. ET on Tuesday, after trading as low as $106.65. The move matters because Rhythm is a single-product rare-disease biotech whose stock has tended to swing on regulatory and clinical milestones for Imcivree, its obesity drug. Investors are watching the…
30 December 2025
···
Regencell Bioscience stock jumps 11% as RGC volatility returns ahead of Tuesday’s open

Regencell Bioscience stock jumps 11% as RGC volatility returns ahead of Tuesday’s open

NEW YORK, December 30, 2025, 05:20 ET — Premarket Regencell Bioscience Holdings Ltd shares were last indicated at $23.48 in off-hours trade ahead of Tuesday’s U.S. session. The stock ended Monday up 10.96% at $23.48, after trading as low as $19.80 and as high as $25.50, with about 723,000 shares changing hands, MarketBeat data showed. Market capitalization was listed at…
30 December 2025
····
Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision

Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision

NEW YORK, December 30, 2025, 01:25 ET — Market closed Outlook Therapeutics, Inc. shares closed Monday up 8.8% at $1.98 after trading between $1.78 and $1.98. The stock was last up about 2% at $2.02 in late after-hours trading, with about 5.7 million shares changing hands. StockAnalysis Traders are zeroed in on a Dec. 31 deadline at the U.S. Food…
30 December 2025
····
Travere Therapeutics (TVTX) Stock Watch: Pre‑Market Focus on the Jan. 13 FDA Decision After a 14% Rally

Travere Therapeutics (TVTX) Stock Watch: Pre‑Market Focus on the Jan. 13 FDA Decision After a 14% Rally

As of 8:54 a.m. ET in New York on Friday, December 26, 2025, U.S. markets are in pre‑market and set to reopen for the regular session at 9:30 a.m. ET. Travere Therapeutics, Inc. (NASDAQ: TVTX) is entering the post‑holiday session with fresh momentum and a very specific catalyst on investors’ minds: an FDA decision deadline of January 13, 2026 for…
26 December 2025
···
ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

December 22, 2025 — ABIVAX Société Anonyme (ticker ABVX on Nasdaq and Euronext Paris) is back in the spotlight today, with traders juggling two storylines that can move a biotech stock fast: renewed takeover speculation involving Eli Lilly and Abivax’s addition to the Nasdaq Biotechnology Index (NBI), effective before today’s market open. GlobeNewswire In early market action, multiple outlets reported…
22 December 2025
····
Vertex Pharmaceuticals (VRTX) Stock Week Ahead: Holiday-Shortened Trading, New Gene-Therapy Data, and Fresh Analyst Targets (Dec. 22–26, 2025)

Vertex Pharmaceuticals (VRTX) Stock Week Ahead: Holiday-Shortened Trading, New Gene-Therapy Data, and Fresh Analyst Targets (Dec. 22–26, 2025)

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) heads into the week of December 22–26, 2025 with a familiar setup for biotech investors: a cash-rich market leader in cystic fibrosis (CF), a pipeline that could meaningfully diversify revenue over the next 12–24 months, and a stock that can move quickly on headlines—even when broader markets are quiet. The difference this time is the…
22 December 2025
···
BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is ending 2025 with a bang. Shares surged on Friday, December 19, closing at $61.15—up 17.71% on the day—after the company announced a $4.8 billion all-cash acquisition of rare-disease peer Amicus Therapeutics. Trading volume spiked to roughly 18.5 million shares, far above BioMarin’s recent daily activity, underscoring how dramatically the market repriced the story in…
21 December 2025
····
1 2 3 4 5 … 12

Stock Market Today

  • NNN REIT trades at discount to DCF-based value; price US$42.64 vs intrinsic US$77.61
    January 18, 2026, 12:18 PM EST. NNN REIT trades at US$42.64, with 7-day, 30-day and YTD gains of 3.9%, 7.2% and 7.9%. Over 1 year it's up 12.8% and 5 years 37.6%. Simply Wall St assigns a valuation score of 5/6, citing the stock as undervalued on most checks. A two-stage DCF framework uses trailing free cash flow of about $616.6 million and projects $977.6 million in 2035, yielding an intrinsic value of US$77.61 per share and a 45.1% discount to the current price. The takeaway is that the stock looks undervalued on this model, though investors weigh the stability of a REIT against growth prospects; outcomes depend on cash-flow assumptions.
Go toTop